CANCER-RELATED FATIGUE
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cancer-related fatigue (CRF) is the most commonly reported symptom in patients with cancer with a prevalence up to 100%. It has a significant negative impact on quality of life. An effective management of CRF could significantly reduce the disease burden associated with cancer and its treatment. Unfortunately, the underlying pathophysiology is very complex and not uniform. This article reviews the possible therapy of contributing factors, nonpharmacological treatment, such as exercise and psychosocial interventions, and pharmacologic approaches in managing CRF. Numerous drugs, such as psychostimulants (methylphenidate, dexamphetamines, modafinil and pemoline), antidepressants, corticosteroids, L-carnitine, donepezil and guarana have been studied. Methylphenidate, modafinil and guarana show the most promising results so far. However, additional randomized, placebo-controlled trials are needed to determine the benefit of these and other drugs in the treatment of CRF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exercise for the management of cancer-related fatigue in adults
Cramp, F., & Byron-Daniel, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006145.pub3 · Cited by 1,096
Cancer-related fatigue: the scale of the problem
Hofman, M., Ryan, J. L., Figueroa-Moseley, C. D., Jean-Pierre, P., & Morrow, G. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-s1-4 · Cited by 895 · cited 3×
“It affects adversely a person’s emotional, physical and mental well-being (2, 3).”
BackgroundStone, P., Richardson, A., Ream, E., Smith, A. G., Kerr, D. J., & Kearney, N. (2000) · Annals of Oncology · doi:10.1023/a:1008318932641 · Cited by 438
Kangas, M., Bovbjerg, D. H., & Montgomery, G. H. (2008) · Psychological Bulletin · doi:10.1037/a0012825 · Cited by 428 · cited 2×
“Multimodal exercise or single mode such as walking programs, cardiovascular or fl exibility training, and resistance training were found to have moderate benefi t for reducing CRF (24, 25).”
BackgroundMorrow, G. R., Hickok, J. T., Roscoe, J. A., Raubertas, R. F., Andrews, P. L. R., Flynn, P. J., Hynes, H. E., Banerjee, T. K., Kirshner, J. J., & King, D. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.070 · Cited by 324 · cited 1×
“At least three placebocontrolled, randomized trials in patients without a depressive mood disorder undergoing cancer treatment failed to demonstrate any improvement in fatigue in patients randomly assigned to empirically receive selective serotonin re-uptake inhibitors (paroxetine (38, 39), sertraline (40)), although…”
BackgroundButler, J. M., Case, L. D., Atkins, J., Frizzell, B., Sanders, G., Griffin, P., Lesser, G., McMullen, K., McQuellon, R., Naughton, M., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.076 · Cited by 214 · cited 2×
“(32) 68 patients with primary or metastatic brain tumour receiving radiation therapy Prospective, phase III, double-blind, placebocontrolled RCT No difference in CRF between drug and placebo 8 weeks after end of radiation; no effi cacy of drug in preventing CRF High dropout rate; small sample size”
Background
Cited by
Xunlin, N., Lau, Y., & Klainin-Yobas, P. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-019-05219-9 · Cited by 243
The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory
Wigmore, P. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_235 · Cited by 66
Cancer-related fatigue: impact on patient quality of life and management approaches
Yeo, T. P., & Cannaday, S. (2015) · Nursing: Research and Reviews · doi:10.2147/nrr.s41957 · Cited by 21
Fang, H., Sun, Y., Yu, D., & Xu, Y. (2024) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2024.100515 · Cited by 12
Metadata
- Authors
- De Waele, S., & Van Belle, S.
- Venue
- Acta Clinica Belgica
- Publisher
- Informa UK Limited
- Published
- 2010-12
- Volume
- 65
- Issue
- 6
- Pages
- 378-385
- ISSN
- 1784-3286 (ISSN-L)
- 2295-3337
- OpenAlex
- W2074728935
- Cited by
- 26
- References
- 6
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.